Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15240528rdf:typepubmed:Citationlld:pubmed
pubmed-article:15240528lifeskim:mentionsumls-concept:C1516213lld:lifeskim
pubmed-article:15240528lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:15240528lifeskim:mentionsumls-concept:C0153690lld:lifeskim
pubmed-article:15240528lifeskim:mentionsumls-concept:C0011777lld:lifeskim
pubmed-article:15240528lifeskim:mentionsumls-concept:C0547070lld:lifeskim
pubmed-article:15240528lifeskim:mentionsumls-concept:C1306673lld:lifeskim
pubmed-article:15240528lifeskim:mentionsumls-concept:C1442989lld:lifeskim
pubmed-article:15240528lifeskim:mentionsumls-concept:C1515985lld:lifeskim
pubmed-article:15240528lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:15240528lifeskim:mentionsumls-concept:C0732165lld:lifeskim
pubmed-article:15240528pubmed:issue13lld:pubmed
pubmed-article:15240528pubmed:dateCreated2004-7-8lld:pubmed
pubmed-article:15240528pubmed:abstractTextAndrogen ablation-refractory prostate cancer patients (stage D3) develop painful bone metastases and limited responsiveness to conventional therapies, hence the lack of universally accepted "gold standard" treatment for this poor prognosis clinical setting. We tested the safety and efficacy in stage D3 patients of the combination hormonal therapy, which combines administration of somatostatin analog and dexamethasone with standard androgen ablation monotherapy (luteinizing-hormone releasing-hormone analog or orchiectomy).lld:pubmed
pubmed-article:15240528pubmed:languageenglld:pubmed
pubmed-article:15240528pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15240528pubmed:citationSubsetIMlld:pubmed
pubmed-article:15240528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15240528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15240528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15240528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15240528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15240528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15240528pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15240528pubmed:statusMEDLINElld:pubmed
pubmed-article:15240528pubmed:monthJullld:pubmed
pubmed-article:15240528pubmed:issn1078-0432lld:pubmed
pubmed-article:15240528pubmed:authorpubmed-author:KoutsilierisM...lld:pubmed
pubmed-article:15240528pubmed:authorpubmed-author:DimopoulosThe...lld:pubmed
pubmed-article:15240528pubmed:authorpubmed-author:TsintavisAtha...lld:pubmed
pubmed-article:15240528pubmed:authorpubmed-author:Milathianakis...lld:pubmed
pubmed-article:15240528pubmed:authorpubmed-author:BogdanosJohnJlld:pubmed
pubmed-article:15240528pubmed:authorpubmed-author:Karamanolakis...lld:pubmed
pubmed-article:15240528pubmed:authorpubmed-author:MitsiadesCons...lld:pubmed
pubmed-article:15240528pubmed:issnTypePrintlld:pubmed
pubmed-article:15240528pubmed:day1lld:pubmed
pubmed-article:15240528pubmed:volume10lld:pubmed
pubmed-article:15240528pubmed:ownerNLMlld:pubmed
pubmed-article:15240528pubmed:authorsCompleteYlld:pubmed
pubmed-article:15240528pubmed:pagination4398-405lld:pubmed
pubmed-article:15240528pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:meshHeadingpubmed-meshheading:15240528...lld:pubmed
pubmed-article:15240528pubmed:year2004lld:pubmed
pubmed-article:15240528pubmed:articleTitleCombination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.lld:pubmed
pubmed-article:15240528pubmed:affiliationDepartment of Experimental Physiology, Medical School, University of Athens, Goudi-Athens, Greece. mitsiades@dfci.harvard.edulld:pubmed
pubmed-article:15240528pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15240528lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15240528lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15240528lld:pubmed